# A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

> **NCT02927067** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 553 (actual)

## Conditions studied

- Cytomegalovirus (CMV)

## Interventions

- **DRUG:** Maribavir
- **DRUG:** Valganciclovir
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02927067
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-14
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 553 (ACTUAL)
- **Last updated:** 2023-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927067, "A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02927067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*